Aby J. Mathew - Jul 19, 2023 Form 4 Insider Report for BIOLIFE SOLUTIONS INC (BLFS)

Role
EVP & Chief Scientific Officer
Signature
/s/ Aby J. Mathew
Stock symbol
BLFS
Transactions as of
Jul 19, 2023
Transactions value $
-$364,100
Form type
4
Date filed
7/24/2023, 04:35 PM
Previous filing
Jun 29, 2023
Next filing
Aug 16, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction BLFS Common Stock Options Exercise $20.6K +10K +3.68% $2.06* 282K Jul 19, 2023 Direct
transaction BLFS Common Stock Sale -$205K -10K -3.55% $20.46 272K Jul 19, 2023 Direct F2, F3
transaction BLFS Common Stock Options Exercise $20.6K +10K +3.68% $2.06* 282K Jul 20, 2023 Direct
transaction BLFS Common Stock Sale -$201K -10K -3.55% $20.07 272K Jul 20, 2023 Direct F2, F4

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction BLFS Employee Stock Option Options Exercise $0 -10K -14.29% $0.00 60K Jul 19, 2023 Common Stock 10K $2.06 Direct F1
transaction BLFS Employee Stock Option Options Exercise $0 -10K -16.67% $0.00 50K Jul 20, 2023 Common Stock 10K $2.06 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 On May 4, 2015, the reporting person was granted an option to purchase 229,837 shares of common stock which vested 25% on the first anniversary of the grant date, and in 36 equal monthly installments thereafter.
F2 The sales reported were effected pursuant to a Rule 10b5-1 (c) trading plan adopted by the reporting person effective as of 11-15-2022.
F3 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $20.24 to $20.84, inclusive. The reporting person undertakes to provide to the registrant, any security holder of the registrant, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
F4 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $20.00 to $20.17, inclusive. The reporting person undertakes to provide to the registrant, any security holder of the registrant, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.